https://scholars.lib.ntu.edu.tw/handle/123456789/554466
標題: | Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration | 作者: | Hsia Y. CHANG-HAO YANG YI-TING HSIEH CHUNG-MAY YANG TZYY-CHANG HO TSO-TING LAI |
關鍵字: | Antivascular endothelial growth factor; Hyperreflective foci; Neovascular age-related macular degeneration; Subretinal fluid | 公開日期: | 2020 | 出版社: | Springer | 卷: | 258 | 期: | 2 | 起(迄)頁: | 273-280 | 來源出版物: | Graefe's Archive for Clinical and Experimental Ophthalmology | 摘要: | Purpose: To describe the optical coherence tomographic findings of hyperreflective foci (HF) in neovascular age-related macular degeneration and evaluate the use of HF to predict visual outcome after antivascular endothelium growth factor (anti-VEGF) therapy. Methods: This was a post-hoc analysis of a retrospective cohort study. Hyperreflective foci were localized in the inner retina, outer retina, or subretinal fluid (SRF) layer. The treatment response of HF was recorded. The association between HF and visual outcome was analyzed. Results: We enrolled 126 eyes. Hyperreflective foci involving more than one layer were associated with poor initial visual acuity (P < 0.001). Hyperreflective foci in each layer at baseline were negatively correlated with baseline visual acuity. At 3 months posttreatment, HF in the SRF layer had decreased significantly (P = 0.003), which was faster compared with HF in other layers. Baseline HF status at each layer was not associated with final visual outcome. The eyes with reduced HF in the SRF at 3 months had better visual improvement at 12 months (P = 0.038). Conclusion: Hyperreflective foci involving multiple layers were associated with poor initial visual acuity but not with final visual outcome. With anti-VEGF treatment, HF in the SRF layer resolved faster, which may predict better visual outcome. ? 2019, Springer-Verlag GmbH Germany, part of Springer Nature. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076587292&doi=10.1007%2fs00417-019-04546-1&partnerID=40&md5=b067951f1502c0b7bc2a694794b8fb03 https://scholars.lib.ntu.edu.tw/handle/123456789/554466 |
ISSN: | 0721-832X | DOI: | 10.1007/s00417-019-04546-1 | SDG/關鍵字: | aflibercept; ranibizumab; vasculotropin antibody; aflibercept; angiogenesis inhibitor; fusion protein; ranibizumab; vasculotropin receptor; aged; Article; best corrected visual acuity; cohort analysis; controlled study; correlational study; disease association; external limiting membrane; female; fluorescence angiography; human; hyperreflective foci; inner retina; major clinical study; male; optical coherence tomography; post hoc analysis; priority journal; retrospective study; subretinal fluid; treatment outcome; treatment response; visual acuity; visual system parameters; wet macular degeneration; eye refraction; follow up; intravitreal drug administration; optical coherence tomography; pathology; physiology; procedures; retina macula lutea; visual acuity; wet macular degeneration; Aged; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Male; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Refraction, Ocular; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。